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Ceramides and sphingolipids make up major portions of the plasma membrane and 
therefore are crucial for cell proliferation, survival, and death. With dysregulation comes 
numerous pathophysiological conditions, such as Alzheimer's, Huntington's Disease, 
Creutzfeldt-Jakob, cardiovascular disease, and many cancers. However, the regulation of 
the enzymes responsible for catalyzing the formation of ceramides is still not well 
understood. In this experiment, three isoforms were of focus: CerS2, CerS5, and CerS6. 
Through mRNA, protein, and immunofluorescence analysis, it can be concluded that these 
isoforms do indeed interact within the human cell in order to upregulate their activity. It 
was also found that cells made to overexpress CerS2 also tend to express CerS5 and CerS6 
to the point of interaction between the two proteins.
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CHAPTER 1 
 
 
 
Introduction 
 
 
Sphingolipid metabolism 
 Sphingolipids are critical regulators of cell growth and differentiation and their 
dysregulation has been shown to induce stress responses that will eventually lead to 
various diseases, including Alzheimer’s, Huntington’s, cardiovascular disease, and human 
cancers. This class of lipid molecules, which contains a sphingosine backbone, make up a 
crucial portion of eukaryotic plasma membranes by defining the physical aspect of said 
membrane. They are heavily engaged at various levels of biological functions and have 
been thought of as being capable of producing second messenger metabolites as well as 
acting as second messengers themselves (Zheng et al., 2006).  
 Sphingolipids can have a variety of fatty acid chain lengths and it has been 
postulated that those lengths will have a downstream effect on pro-apoptotic or pro-
survival signaling. The sphingoid backbone is typically O-linked to a charged head group 
(which typically determines the molecule’s nomenclature) and amide-linked to an acyl 
group. In humans, the primary sphingolipids are sphingosine (d18:1), sphinganine (d18:0), 
and 4-hydroxysphinganine (t18:0), though sphingolipid composition has been observed to 
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rapidly change and therefore alter membrane structure in response to stimulus (Zheng et 
al., 2006). De novo sphingolipid synthesis begins with the condensation reaction between 
serine and a fatty acyl-CoA (typically palmitoyl-CoA) to form 3-ketosphinganine via 
serine palmitoyltransferase. 3KSa is reduced to sphinganine via 3-ketosphinganine 
reductase, N-acylated to dihydroceramide, and desaturated to ceramide, all within the 
endoplasmic reticulum.  
 Sphingosine is a long-chain (at 18 carbons), unsaturated amino alcohol that is an 
essential component to sphingolipids. Ceramide degradation via ceramidase hydrolysis has 
been considered to be the only source of intracellular sphingosine as there is not yet a 
direct reaction that can add the appropriate 4,5-double bond to sphinganine (Zheng et al., 
2006). The balance between sphingolipids and ceramides is crucial to the body, not only as 
building blocks and metabolites of one another, but also to maintain a homeostatic balance 
between pro- and anti-apoptotic molecules. Specifically, ceramides and sphingosine 1-
phosphate (S1P), a signaling sphingolipid that also acts as a bioactive mediator, constitute 
a rheostat system in which they maintain balance between cell death via ceramide 
production or cell survival via S1P (Lavieu et al., 2007). S1P is formed from ceramide via 
ceramidase, as was mentioned previously regarding the only known reaction to form 
sphingosine, and then is phosphorylated via one of two sphingosine kinase isoforms. S1P 
did not hold significance to this project in particular, but is of importance to discuss when 
illustrating the body’s lipid and sphingolipid homeostasis.  
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Ceramides 
 Ceramides are sphingolipid molecules composed of an N-acylated sphingosine and 
a fatty acid chain that provide the backbone of all sphingolipids. These N-acylated 
sphingolipids do not consist of any head groups and its only R group is a hydrogen atom. 
The acyl chain can vary in length, with long-chain (C16) and very long-chain (C24) being 
the most predominant in mammalian tissue. Due to the differing lengths of acyl-CoAs that 
are used in production, ceramides are considered a class of molecules rather than a single 
molecule itself of varying forms (Gault et al., 2011), giving rise to the concept of differing 
biological functions which are dependent upon the different chain lengths. 
 Ceramide accumulation at the mitochondria can inhibit telomerase, leading to 
irreversible cell cycle arrest and potentially apoptosis (Hannun and Luberto, 2000; Pettus 
et al., 2002). Hannun and Luberto also noted that simply increasing the concentration of 
intracellular ceramides can induce those same stress responses in the cell. Zheng et al., in 
2006, had also cited studies that had shown the induction of autophagy via addition of 
exogenous ceramides and sphingolipids. Generally, long-chain ceramides (especially C16-
ceramide) are considered to be pro-apoptotic while very long-chain are anti-apoptotic 
(Mesicek et al., 2010). That balance is important in order to maintain homeostasis and a 
shift from C24- to C16-ceramides has caused an increase in apoptotic activity in HeLa cells 
(Sassa et al., 2012). De novo-generated C18- and C16-ceramides have been observed to play 
significant roles regarding apoptosis regulation (Senkal et al., 2010). Mesciek et al. have 
shown that C16:0-ceramide is involved in regulating apoptosis with homeostasis maintained 
by balancing C16- and C24:1-, C24:0-ceramides. In that same 2010 study, ionizing radiation-
4 
induced C16:0-ceramide generation via ceramide synthase 5 was pro-apoptotic whereas IR-
induced C24:1- and C24:0-ceramides via ceramide synthase 2 were pro-survival. 
 
Ceramide synthases 
 Ceramide synthesis comes about in two ways (Figure 1): by hydrolysis of 
sphingolipids via sphingomyelinase (SM) into their constituent parts or de novo synthesis 
with ceramide synthases (CerS) in the ER via the formation of an amide bond between a 
sphingoid base and a fatty acyl-CoA chain (Sassa et al., 2012). Ceramide synthases were 
initially called Lass proteins (“Longevity assurance”) due to their similarity in structure to 
LAG1p (Longevity assurance gene-1) in yeast. CerS are membrane-spanning proteins of a 
proposed odd number of transmembrane domains that utilize acyl-CoA’s of differing 
lengths for one of six possible isoforms and are found throughout the body, though there 
has been little proven correlation between mRNA levels and enzymatic activity (and 
therefore corresponding sphingolipid distribution). Regarding the differing acyl-CoA chain 
lengths, long-chain (C16 to C18) and very long-chain (C20 to C24) are predominant in most 
mammalian tissues (Sassa et al., 2012) and it has been postulated that these enzymes may 
exhibit stereospecificity toward their sphingoid base of choice (Mullen et al., 2012). 
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Figure 1: Ceramide synthesis comes about in two ways. Ceramide synthesis occurs at 
the cytoplasmic leaflet of the ER through the de novo pathway or the sphingosine recycling 
pathway. The de novo pathway begins with the condensation of a serine and a fatty acyl-
CoA via serine-palmitoyl transferase (SPT) to 3-ketosphingosine (3KSa). 3KSa is then 
reduced to sphinganine via 3-ketosphingosine reductase (3-KSR) and then N-acylated to 
dihydroceramide before being desaturated to ceramide. The recycling pathway occurs 
when sphingomyelin undergoes hydrolysis via sphingomyelinase (SM) into ceramide. 
Ceramide degradation via ceramidases (not pictured) is the major source of intracellular 
sphingosine. 
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 Regarding enzyme localization, de novo ceramide synthesis will begin in the ER 
and continue in the Golgi apparatus, which Pettus et al. noted in 2002 via fluorescence and 
time-lapse confocal microscopy. They found that ceramides form within the perinuclear 
region, ER, and mitochondria before accumulating in the Golgi to be metabolized further 
into glucosylceramide and sphingomyelin. CerS activity has been characterized within the 
ER (finding that enzymatic activity is available from the cytosolic leaflet of the ER) and 
mitochondria, but not the Golgi apparatus unless placed under stressors to force 
translocation of certain isoforms (Mullen et al., 2012). Those same researchers saw that 
CerS2 will translocate but neither CerS4 nor CerS5 behaved in that way under those same 
conditions. 
 As mentioned previously, CerS can be classified as one of six isoforms, 
appropriately designated CerS1 through 6. Of these six, CerS2, CerS5, and CerS6 were of 
interest to this project.  
 
Ceramide synthases 2, 5, and 6 
 Not much is currently known about the regulation of CerS, though previous 
research has shown that they rapidly form homo- and heterodimers, showing a significant 
increase in activity level upon formation. CerS2 has been shown to be able to 
immunoprecipitate with CerS5 and CerS6 (Laviad et al., 2012; Mesciek et al., 2010) and 
has shown the highest relative increase in enzymatic activity upon dimerization. CerS5 
expression has been found to be influenced by the availability of other CerS, in that 
depletion of CerS2 or CerS6 has increased CerS5 expression (Wegner et al., 2016). The 
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exact mechanisms for formation of dimers is still unknown, though a model has been 
developed in which the isoforms may bind to one another in order to form heterodimers 
that can then interact allosterically with fellow dimers or with other monomers (Laviad et 
al., 2012; Mesciek et al., 2010). Of the six isoforms, the regulatory mechanisms of CerS2 
and CerS5 are the best understood whereas little is known about CerS6. 
 Wegner et al. showed that a knockdown of CerS2 was accompanied by an increase 
in CerS6 expression, fueling the theory that homeostasis depends upon a balance between 
LC and VLC ceramides. Senkal et al. in 2010 found that downregulation of CerS6 caused a 
decrease in C16-ceramide generation with a compensatory increase in C22- and C24-
ceramide levels.  
 CerS5 and 6 share approximately 61.7% identity and 68.2% similarity (Mizutani et 
al., 2005), catalyze the same length acyl-CoA’s (C14 to C16), and prefer palmitoyl-CoA as 
their main substrate, but are concentrated within different tissues and therefore found at 
different distributions throughout the body. CerS5 mRNA is strongly expressed in muscle 
and brain, with highest detection being in gray and white matter cells, as well as being 
majorly present in lung epithelia. In the heart, CerS5 has been shown to be required for 
cardiomyocyte hypertrophy and autophagy (Russo et al., 2012). The ceramides generated 
by CerS6, on the other hand, have been shown to play a role in ER stress-induced 
apoptosis as well as mitochondrial fragmentation via binding to MFF. CerS6 has been 
shown to be highly expressed in kidney and brain, though there has been little to no 
detection within muscle, spleen, or stomach (Mizutani et al., 2005).  
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Hypothesis 
 The formation of protein dimers has been well observed in nature, with many 
enzymes forming homo- or heterodimers in order to upregulate their activity or improve 
their efficacy. Ceramide synthases are no different, though a lot of their regulation and 
mechanisms still remain unknown. In this project, we wanted to focus on how CerS2 
heterodimerizes with CerS5 or CerS6 and how that drove expression of the constituent 
parts. We believed that the heterodimers would indeed give way for optimal CerS2 
enzymatic activity and expression, based upon proposed regulatory mechanisms and 
previous research conducted on the proteins. We believed that CerS2 forming a 
heterodimer with either CerS5 or CerS6 would drive CerS2 expression above its baseline 
at both the mRNA and protein levels. With the Duolink Proximity Ligation Assay, we 
believed that we would see puncta with both co-transfection conditions, which would 
indicate an interaction between the two proteins of interest, CerS2 and either CerS5 or 
CerS6. We also believed that CerS2 heterodimers with either CerS5 or CerS6 would alter 
its localization to the cell via immunofluorescence.  
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Materials and Methods 
 
Cell culture and reagents: 
 Human and rat ventricular cardiomyocytes (AC16 and H9c2) were obtained from 
the Jackson Laboratory, thawed, and grown out to be utilized for this experiment. AC16 
cells were grown in DMEM/F12 (Sigma Cat. No. D6434) containing 2 mM L-Glutamine 
(EMD Millipore Cat. No. TMS-002-C), 12.5% Fetal Bovine Serum (EMD Millipore Cat. 
No. ES-009-B), and 1% 1X Penicillin-Streptomycin Solution (EMD Millipore Cat. No. 
TMS-AB2-C) at 37°C in a 5% CO2 atmosphere. AC16 cells were to be split at 70-90% 
confluence in a 150 cm2 flask with 5.0 mL 0.05% Trypsin-EDTA with phenol red (Gibco). 
After splitting, the cells were transfected for 24 hours at 70% confluence using the 
Lipofectamine 3000 Kit obtained from Thermo Scientific. 
 H9c2 cells were grown up in DMEM/F10 (Sigma Cat. No. 30-2002) containing 
12.5% FBS (EMD Millipore Cat. No. ES-009-B) and 1% 1X Penicillin-Streptomycin 
Solution (EMD Millipore Cat. No. TMS-AB2-C) at 37°C in a 5% CO2 atmosphere. H9c2 
cells were to be split at 50-70% confluence in a 150 cm2 flask with 5.0 mL Trypsin-EDTA 
with phenol red (Gibco). H9c2 cells were transfected for 24 hours around 70% confluence 
utilizing the same Lipofectamine 3000 kit. 
 Before either of the grown cells were plated out for transfections, each well in a 6-
well plate received a 22mm circular coverslip if the cells were intended to be used for 
either microscopy or Duolink Proximity Ligation Assay. 
10 
 AC16 cells were utilized in more experiments than their H9c2 counterparts due to 
their faster rates of growth and higher level of availability for experiments. 
Cells were checked daily and throughout each step of fixation and preparation in 
order to ensure that they were healthy and were not contaminated. Cells were reviewed 
under a light microscope in order to determine whether they were of appropriate 
confluence and form to be used for experiments. Confluence was estimated by the 
researcher after having been trained in cell health. 
 
 
DNA 
 DNA constructs for CerS2, CerS5, and CerS6 were ordered from GenScript, 
transformed with bacteria via TOP10 Competent Cell kit, and streaked onto agar plates to 
be grown overnight. Colonies were chosen based upon opacity and thickness, picked onto 
a clean pipette tip, dropped into a 15 mL rounded bottom culture tube containing 3 mL LB 
Buffer and Ampicillin, and shaken over the course of a day. The next day, the cultures 
were examined and the cloudiest looking tubes were chosen. 100 µL were taken out from 
the chosen tubes and pipetted into a 150 mL flask of LB Buffer and Amp to be shaken 
overnight at 37°C. The following day, the 150 mL flask was split into three 50 mL tubes 
and spun at 3,000 x g for 20 minutes at room temperature to pellet each mixture before 
going into Maxi Prep per the QIAGEN HiSpeed Plasmid Maxi Kit (cat. no. 12662). 
 Before the Maxi Prep, RNase A solution was added to Buffer P1 and stored at 4°C, 
along with Buffer P3, both included in the kit. Bacterial pellets were resuspended in 10 mL 
11 
Buffer P1, with the first pellet receiving 10 mL, being pipetted up and down in order to 
mix them, then added to the next pellet of the same DNA in order to re-combine the three 
50 mL’s from the original 150 mL flask. Once the pellets are homogenized and in a single 
50 mL tube, 10 mL Buffer P2 was added and the tube was inverted 4-6 times before being 
incubated at room temperature for 5 minutes. After incubation, 10 mL of Buffer P3 was 
added and mixed by inverting the tube again. The tube was then poured into the barrel of a 
QIAfilter Cartridge with a cap screwed onto the outer nozzle incubated at room 
temperature for 10 minutes without the plunger inserted. 
 During that time, a HiSpeed Tip was equilibrated with 10 mL Buffer QBT via 
gravity filtration. After the incubation, the cap was removed from the cartridge and the 
plunger was inserted, pushing out the cell lysate slowly into the HiSpeed Tip. Once the 
lysate had passed through the filter, the HiSpeed Tip was washed with 60 mL Buffer QC 
and then the DNA was eluted into a 50 mL tube with 15 mL Buffer QF. 
 10.5 mL isopropanol was added to the DNA for precipitation, mixed and incubated 
at room temperature for 5 minutes. During that time, a plunger was removed from a 30 mL 
syringe and screwed onto a QIAprecipitator Module. The QIAprecipitator and plunger was 
placed over a waste bin and the eluate-isopropanol mixture was added to the syringe and 
filtered through the precipitator. The QIAprecipitator was removed from the syringe in 
order to pull out the plunger and then reattached before adding 2 mL 70% ethanol to the 
syringe to wash the DNA. The precipitator was removed to pull out the plunger and then 
reattached before inserting the plunger and pressing air through the precipitator to dry the 
membrane. The QIAprecipitator was then moved onto a 5 mL syringe and held over a 1.5 
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mL collection tube. 1 mL Buffer TE was added to the syringe and pushed through to elute 
the DNA into the 1.5 mL collection tube. That last step was repeated in order to maximize 
DNA concentration. That DNA was then used for transfections. 
 
Transfections 
 Each transfection condition’s mastermix was initially mixed in two different tubes 
before they were combined. The first set of mastermixes was composed of, per well, 125 
µL Opti-MEM Reduced Serum Media (Thermo Fisher) and either 3.75 or 7.5 µL of 
Lipofectamine 3000. Transfections of CerS2 and CerS6 as well as co-transfections of 
CerS2 with CerS5 and CerS2 with CerS6 were accomplished with 7.5 µL of lipofectamine 
whereas pcDNA and CerS5 both utilized 3.75 µL of lipofectamine. The second set of 
mastermixes was 125 µL of Opti-MEM, 5 µL of p3000, and 5 µg of DNA for each 
transfection condition. After allowing the DNA mixture to sit for approximately 10 
minutes, the two tubes were mixed and an equal amount was pipetted into each appropriate 
well. Each well also received a media change prior to transfection. The transfection media 
sat for 24 hours and then was removed prior to fixation or cell processing. 
 
Co-localization microscopy experiments 
 After the 24 hour transfection, the media was removed from each well before 2 mL 
of -20°C methanol was added and the plate was put into a -20°C freezer for 15-30 minutes. 
Then, at room temperature, the methanol was removed and each coverslip was blocked in 
5% BSA Fraction V-1X PBS with 10 mM glycine and 0.1% Triton-X for 30 minutes. 
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Antibodies (Lass2 C-11 from Santa Cruz, sc-390745, raised in mouse; Lass5 PA5-20569 
from Thermo Scientific, raised in rabbit; Lass6 PA5-20648 from Thermo Scientific, raised 
in rabbit) were diluted to 1:100 in 1% BSA Fraction V-PBS-gly. Lass2 had to be raised in 
a different animal to Lass5 and Lass6 in order to best utilize immunofluorescence to 
determine co-localization. The blocking solution was removed and 50 µL of the antibody 
solution was placed on a clean sheet of parafilm onto which each corresponding coverslip 
was flipped. The coverslips were incubated for 30 minutes at room temperature. The 
coverslips were incubated for 30 minutes at room temperature, flipped back into a clean 6-
well plate with the cell side up, and then washed three times with 1X PBS for five minutes 
each. Secondaries (goat anti-mouse fluor 488 and chicken anti-mouse fluor 594, both 
obtained from Thermo Scientific) were diluted to 1:400 in the same 1% BSA Fraction V-
PBS-glycine. 50 µL of the secondaries were pipetted onto a new sheet of clean parafilm 
onto which the now washed slides were flipped. The coverslips were incubated in the dark 
for 30 minutes then washed again with 1X PBS for five minutes each. The coverslips were 
then mounted with a drop of 10 mM n-Propyl gallate in glycerol, the excess was lightly 
dabbed off with a Kimwipe, and sealed with clear nail polish. The slides dried for 
approximately 30 minutes in the dark before they were stored at 4°C to the imaged the next 
day. 
 
Duolink Proximity Ligation Assay 
 After 24 hour transfections, the media was removed from each well and each 
coverslip received approximately 2 mL of 4% paraformaldehyde and sat at room 
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temperature for 15 minutes for cell fixation. The PFA was removed then the coverslips 
were quenched with three 1X PBS-glycine washes for five minutes each. A clean piece of 
parafilm was cut to size and a droplet of the blocking solution included in the Duolink 
PLA kit was added for each coverslip. Coverslips were inverted over the droplet so the cell 
side faced the droplet and each slip was incubated for 30 minutes in a 37°C chamber. 
During this time, primary antibodies (the same Lass2, Lass5, and Lass6 used in co-
localization immunofluorescence experiments as well as COX4 for a mitochondrial 
marker) were diluted in combinations of Lass2 and Lass5 or Lass6 (all being combined 
with COX4) at 1:50 in the antibody diluent included in the Duolink PLA kit. After the 30 
minute incubation, 50 µL of the antibody solution was pipetted onto another clean sheet of 
parafilm and coverslips were placed onto each drop to sit at room temperature for two and 
a half hours. 
 After primary antibody incubation, coverslips were washed twice for five minutes 
each with room temperature Buffer A (0.88% NaCl, 0.12% Trizma Base, 0.005% Tween, 
all from Sigma Aldrich, water to 1 L, pH 7.4, filtered through 0.22 µm filter paper via 
gravity filtration). PLA secondary anti-rabbit plus and anti-rabbit mouse minus probes, 
included in the Duolink secondary kits, were diluted at 1:5 with the same antibody diluent 
for primary antibodies. Chicken anti-goat fluor 488 secondary antibody was diluted at 
1:400 and mixed with the PLA probe solutions Approximately 40 µL were pipetted onto a 
clean sheet of parafilm for each coverslip, onto which each slip was flipped over and then 
incubated in a 37°C chamber for one hour. 
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 Toward the end of the hour for the PLA probe incubation, ligation stock from the 
Duolink in situ Detection Reagents kit from Sigma Aldrich was diluted 1:5 with nuclease-
free water. Ligase from the same kit was diluted 1:40 in that ligation-water solution. The 
coverslips were taken off the parafilm and placed into a clean 6-well plate cell side up for 
two Buffer A washes for five minutes each. 30 µL of the ligation-ligase was pipetted onto 
clean parafilm onto which each coverslip was flipped and then incubated for 30 minutes at 
37°C. 
 As the ligation reaction incubation period ended, AMP stock from the Duolink in 
situ Detection Reagents kit was diluted 1:5 with nuclease-free water. Polymerase from that 
same kit was added at 1:80 to the AMP solution. The coverslips were removed from the 
parafilm and put into a clean 6-well plate for two Buffer A washes at two minutes each. 40 
µL of the AMP-polymerase solution were pipetted onto clean parafilm and slips were 
incubated at 37°C in the dark for 100 minutes. After the incubation, slips were flipped back 
into the 6-well plate for two room temperature Buffer B (0.584% NaCl, 0.424% Trizma 
Base, 2.6% Tris-HCl, all from Sigma Aldrich, water to 1L, pH 7.5, filtered through 0.22 
µm filter paper via gravity filtration) for ten minutes each. The slips were then washed 
once in 0.01X Buffer B diluted with nuclease-free water, for one minute each. Coverslips 
were mounted with 1 µL of Duolink Mounting Medium with DAPI and sealed with clear 
nail polish. Slides were left to dry in the dark for approximately 30 minutes before being 
stored at 4°C to be imaged the next day. 
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Confocal microscopy 
 All microscopy images were taken on a Zeiss LSM 700 microscope. All 
microscope operators were trained on the microscope prior to first usage and had a practice 
run in which they would take slide images with a microscopy faculty member. Both co-
localization immunofluorescence and Duolink experiments were evaluated using confocal 
microscopy. Laser intensities and gain were set with a positive set at the beginning of the 
microscopy session, checked against the negative controls, and then were not adjusted 
throughout an imaging set. All images were taken on 63x oil objective. Microscopy was 
performed at the VCU Microscopy Facility, support part, by funding from NIH-NCI 
Cancer Center Support Grant P30 CA016059. 
 
Protein processing and western blots 
 AC16 cells were split into 6-well plates without coverslips and were transfected as 
described previously once the cells reached appropriate confluence. After the 24 hour 
transfection, the media was removed and 100 µL of RIPA+PPI were added to each well in 
order to solubilize the cell layer for scraping to remove the protein. Each tube received a 
hard spin at 10,000 x g for 15 minutes at room temperature. Protein concentration was 
determined via BCA assay (kit from Thermo Scientific) with the samples diluted at 1:10 in 
RIPA+PPI and read at 460 nm. Readings were normalized to four standard: 0 µg/µL, 500 
µg/µL, 1000 µg/µL, and 2000 µg/µL. Protein was then diluted with RIPA in order to reach 
1 µg/µL and 4x Laemmeli diluted 3:4 with betamercaptoethanol to reach 200 µL total 
volume. The samples were boiled for five minutes before being loaded into a 10% 
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Criterion Stain-Free precast electrophoresis gel from Bio-Rad and run at 225V for 30 
minutes immersed in 1X Running Buffer. Gels were then removed from the plastic casing, 
activated via Bio-Rad imager, and transferred onto a PVDF membrane for ten minutes. 
Blots were blocked in 5% FAF BSA in TBST for 30 minutes on a rocker at room 
temperature and the same Lass antibodies as previously mentioned for microscopy 
experiments were diluted 1:1000 in the same 5% BSA-TBST as the blocking solution. The 
antibody dilutions were applied to each appropriate blot after blocking and blots were 
incubated at 4°C overnight on a rocker. 
 The next day, blots were brought to room temperature for an hour before being 
washed thrice with 1X TBST for ten minutes at a time. The same fluorescent secondary 
antibodies as the microscopy experiments were diluted 1:2000 in 5% BSA-TBST and 
applied to each blot, which sat at room temperature in the dark on a rocker for an hour. The 
blots were then washed thrice once more before image capture on the Bio-Rad imager. 
 
RNA, cDNA, and qPCR 
 AC16 cells were grown up in 6-well plates without coverslips and transfected when 
they reached appropriate confluence. After the 24 hour transfection period, the media was 
removed and each well received 1 mL Trizol to be pipetted into appropriately labeled 
tubes. RNA isolation began with a room temperature incubation of the homogenized 
samples for five minutes to allow for complete dissociation of nucleoprotein complexes. 
0.2 mL of chloroform per 1 mL of Trizol was added to each tube, which were then shaken 
vigorously by hand for 15 seconds before another room temperature incubation for two to 
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three minutes. The tubes were then centrifuged at 12,000 x g for 15 minutes at 4°C for the 
mixture to separate into a lower red phenol-chloroform phase, an interphase, and a 
colorless upper aqueous phase that contained the RNA. 
 That aqueous phase was transferred to a fresh tube and the remaining organic phase 
and interphase were discarded. The RNA was precipitated from the aqueous solution via 
the addition of 0.5 mL isopropyl alcohol per 1 mL of Trizol used for initial 
homogenization. Up to 700 µL of the sample was transferred to an RNeasy Mini spin 
column placed into a collection tube at a time, before being centrifuged for 15 seconds at 
10,000 x g. The flow-through was discarded and that step was repeated for any remaining 
sample. 700 µL of Buffer RW1, included in the RNeasy kit, was added to the spin column 
and the tubes were centrifuged for 15 seconds at 10,000 x g, again discarding flow-
through. 500 µL of Buffer RPE was added, the tubes were centrifuged for 15 seconds at 
10,000 x g, and flow-through was discarded. The step was repeated with the amount of 
RPE, though the tubes were then centrifuged for two minutes at that same speed. The 
RNeasy spin column was then placed into a new 2 mL collection tube and centrifuged at 
10,000 x g for one minute to dry the membrane. The RNeasy column was then placed into 
a new 1.5 mL collection tube and 35 µL of RNase-free water was added directly to the 
membrane without contacting it. The tubes sat at room temperature for ten minutes before 
being centrifuged for a minute at 10,000 x g to elute the RNA.  
RNA concentration was measured via Nanodrop in order to determine the amount 
of RNA, nuclease-free water, and iScript solution to reach 250 ng/µL at a final volume 
of20 µL in 0.5 mL tubes. The new tubes were placed in the thermal cycler and processed 
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per the iScript program for cDNA creation. cDNA is a term that describes an mRNA 
transcript’s sequence that is expressed as DNA bases, rather than RNA bases. cDNA 
probes only contain exons and does not include the introns that were spliced out during 
translation from DNA to mRNA. Once the program finished, the samples were diluted 
with 180 µL of nuclease-free water and kept at -80°C for long-term storage. 
qPCR mastermixes were comprised of, in µL/tube, 10 µL SYBR Green from Bio-
Rad, 7 µL nuclease-free water, 2 µL of 10 mM forward and reverse primer solution, and 1 
µL of 2.5 ng cDNA. Primers for qPCR were hGAPDH, hCerS2, hCerS5, and hCerS6 from 
Thermo Scientific. Each plate was a different primer in order to minimize confusion and 
samples were done in triplicate. Samples were laid out in the following order: 
Untransfected, pcDNA, hCerS2, hCerS5, hCerS6, hCerS2 and hCerS5 co-transfection, 
hCerS2 and hCerS6 co-transfection. After normalization with the four standard amounts, 
qPCR results were analyzed and graphed per an Excel ddCt algorithm, which is utilized in 
order to measure relative changes in gene expression compared to that of the reference 
gene. The y-axis of each qPCR graph represented fold change of the level of cDNA in each 
sample when run with a specific primer and acts as a method to analyze the relative 
changes in each gene’s expression. 
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Results 
 
CerS co-overexpression drives expression of the CerS species at the mRNA level 
 qRT-PCR, or simply qPCR, is an experimental tool used in order to measure the 
level of gene expression in a cDNA sample. The AC16 samples run were untransfected 
(abbreviated to UT) and pcDNA as the two  negative controls versus the experimental 
transfection conditions: CerS2, CerS5, CerS6, CerS2 co-expressed with CerS5 
(abbreviated to CerS2+5), and CerS2 co-expressed with CerS6 (abbreviated to CerS2+6). 
The primers run were each 10 mM mixtures of forward and reverse hGAPDH, hCerS2, 
hCerS5, and hCerS6. Figure 2A shows that hGAPDH was an appropriate housekeeping 
gene in that each sample’s cDNA level is equal and their expressions do not exhibit any 
fold change. 
qPCR, in this project, not only confirmed the respective identities of the DNA 
constructs that were utilized for transfection but also showed that co-transfection of CerS2 
with either CerS5 or CerS6 drove gene expression more compared to that of its individual 
transfection. The hCerS2 primer showed that CerS2 and the two co-transfections had the 
highest levels of cDNA gene expression with CerS2 around 2000, CerS2+5 around 3000, 
and CerS2+6 around 11000 fold change compared to those levels in hGAPDH (Figure 2B). 
The qPCR showed that CerS2+6 does drive CerS2 expression to a much higher extent than 
that of CerS2+5. The hCerS5 and hCerS6 primers (Figure 2C and 2D, respectively) 
showed a similar result, though hCerS5 had significantly lower fold changes, as 
represented by the smaller range of its y-axis in Figure 2C, which may be due to the 
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differing binding affinities of these qPCR primers. CerS2+6 had approximately a 200-fold 
change over CerS6 alone, which does still show an increase in gene expression though 
maybe not a significant one, given that the CerS6 sample alone already showed a 1300 fold 
change compared to that of hGAPDH. 
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Figure 2: Co-transfections of two CerS isoforms will drive gene expression levels. (A) 
hGAPDH acted as an appropriate reference gene for this set of qPCR’s, as shown by the 
consistent and low expression levels throughout all samples, including the two negative 
controls. They were all even and equal. Results for the three experimental primers were 
normalized to these values. (B) With hCerS2, it was very clear that the co-transfection of 
CerS2 and CerS6 (CerS2+6) drove CerS2 expression almost 8000-fold over the expression 
of CerS2 alone. The co-transfection of CerS2 and CerS5 (CerS2+5) also increased CerS2 
levels by about 1000-fold, showing that co-transfections with both CerS5 and CerS6 can 
allow CerS2 to dimerize and upregulate its level of cDNA. (C) The level of fold change of 
hCerS5 expression compared to that of hGAPDH is lower than that of the other primers, 
but CerS5 still has at least a 10-fold change above the two negative controls. As was seen 
with the hCerS2 primer, CerS2+5 increased the level of gene expression by 70-fold. (D) 
The CerS6 solo transfection had a very strong level of expression, with the CerS2 and 
CerS6 co-transfection being about 100-fold higher. 
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CerS2 localizes differently compared to CerS5 and CerS6 
 AC16 coverslips were transfected and prepared for immunofluorescence 
experiments with images taken on a confocal microscope. AC16 cells were primarily used 
for these localization experiments due to their higher rate of growth and therefore their 
larger availability. Laser strengths were set via individual transfection conditions (Figure 
4) and then checked against negative controls (Figure 3) in order to confirm that the last 
intensities were appropriate. Images were taken on a confocal LSM 700 microscope at 63x 
oil objective. Exposure to all confocal microscope images was increased by approximately 
30% after image capture to improve clarity. 
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Figure 3: Negative controls for localization immunofluorescence. This set of images 
and experiments served as the negative controls for the localization and co-localization 
immunofluorescence experiments. (A) Both untransfected and pcDNA slides underwent 
the same immunofluorescence protocol as the experimental conditions but did not receive 
any primary antibody. This is to test for secondary antibody specificity and to see if there 
was any background noise that needed to be corrected. (B), (C) Five untransfected and 
pcDNA slides, respectively, underwent that same immunofluorescence protocol in order to 
mimic what was being performed on the experimental condition slides. Confocal laser 
settings were not changed between slides. 
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 The experimental condition slides ultimately showed that CerS2 does localize to 
the cell differently when compared to CerS5 or CerS6 (Figure 4A). When transfected 
individually, the CerS isoforms also seem to have different degrees of fluorescence 
intensity. All CerS isoforms have been previously shown to localize to the ER and the 
CerS2 slide does show exactly that, along with an area of brighter immunofluorescence 
that looks to be localized to the Golgi apparatus. Even when co-transfected with CerS5 or 
CerS6, that Golgi bright spot remains, potentially being a result of CerS2 possibly being 
glycosylated in the Golgi. Neither CerS5 nor CerS6 had that same area. Past AC16 slide 
preparations and imaging have shown a similar bright area in the same region. H9c2 cells 
were not utilized for this experiment due to low availability and time constraints. 
 CerS5 and CerS6 both showed a strong juxtanuclear staining pattern when 
transfected individually. CerS5 seemed to localize to both the ER as well as the 
mitochondria, given the prominent web-like pattern extending outwards from the nucleus. 
CerS6 had the same fluorescence intensity as that of CerS5. The differences in the CerS5 
and CerS6 localizations when compared to that of CerS2 and each other may be a result of 
undergoing different post-translational modifications at the time of cell fixation. 
MitoTracker would have been a helpful tool in order to truly determine localization to the 
mitochondria though it was not included in this experiment due to time constraints and 
should absolutely be a consideration for any future iterations of this project. 
 Co-transfected AC16 cells are shown in B and C of Figure 4. The constructs and 
antibodies utilized remained the same throughout all the localization experiments. In both 
co-transfections, CerS2 still has a bright area in the region of the Golgi that is not present 
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in either CerS5 or CerS6. In 4B, the CerS2 displays a much bright immunofluorescence 
compared to that of CerS5 as well as to the individual CerS2 transfection. Regarding any 
true co-localization, there does seem to be one spot in CerS2+6, indicated by an arrow.  
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Figure 4: CerS2 localizes differently to the cell compared to CerS5 and CerS6. 
Confocal microscopy images were altered to an increased exposure of approximately 30%. 
Green represents the anti-mouse secondary for the Lass2 antibody (488 fluor) while red 
represents the anti-rabbit secondary used for Lass5 and Lass6 (fluor 555). (A) Each of the 
individual transfections were treated with their respective antibody and imaged. 
CerS2/Lass2 does shown a different pattern and level of intensity of fluorescence 
compared to that of CerS5/Lass5 and CerS6/Lass6, which share similar staining patterns. 
(B) and (C) The co-transfections confirmed that CerS2 did localize differently when 
compared to its sister isoforms. The purple arrow in (C) indicates an area of co-
localization,  as shown by the yellow coloring of the area of overlap.  
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Endogenous CerS do not interact in H9c2 cells but do in AC16 
 Duolink in situ fluorescence Proximity Ligsation Assay was utilized in this 
experiment for its high specificity and sensitivity regarding detection of endogenous 
protein interactions as well as protein expression levels at the molecular level. Both AC16 
and H9c2 cells were treated in the same manner and underwent the same protocol 
simultaneously. Images were taken on a confocal microscope at 63x oil object and images 
have been altered for clarity by increasing exposure by approximately 30%. However, no 
puncta were seen in the H9c2 set of slides, as seen in Figure 5. That lack of puncta 
indicates that the proteins of interest were not within 40 nm of each other and therefore 
could not interact with the PLA probes. Even the co-transfections did not reveal any puncta 
in the H9c2 cells. COX4 G-20 antibody was utilized as a mitochondrial marker for the 
Duolink slides. 
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Figure 5: Puncta were not seen in Duolink with H9c2 cells. Blue represents the DAPI 
nuclear staining contained within the mounting medium used for these slides. Green 
represents the COX4 antibody used as a mitochondrial marker. The staining pattern was 
not represented evenly in all coverslips, possibly due to the use of PFA as the fixation 
reagent. (A) The negative controls, Untransfected and pcDNA, treated with both antibody 
combinations and having undergone the entirety of the Duolink experimental protocol. (B) 
No experimental conditions, not even the co-transfections, showed puncta. 
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  AC16 cells, however, did show puncta which would indicate that the proteins of 
interest (the CerS isoforms) are indeed within 40 nm of each other and would be able to 
interact and dimerize. As with the H9c2 cell slides, laser intensities were set using the 
individual transfection conditions and then checked against the negative controls to ensure 
that they were adequate. Figure 6 shows the negative controls for the AC16 set, this time 
including a slide for secondary only. 
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Figure 6: Negative controls for AC16 Duolink. The negative control panel utilizing 
Untransfected and pcDNA slides confirmed that there was no background that required 
correcting in the experimental sides nor were the antibodies non-specific. With the 
secondary only condition, it confirms that the PLA probes were specific for this 
experiment. Blue represents DAPI nuclear staining from the mounting media and green 
represents the COX4 mitochondrial staining. The pattern of the staining seems to be a 
result of the PFA staining, as does the unequal expression across all slides. 
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The major aspect of Duolink that differs from other forms of immunofluorescence 
is the usage of Proximity Ligation Assay (PLA) probes, which bind to the primary 
antibody and are combined with short synthetic strands of DNA. If the proteins of interest 
are within the 40 nm that the PLA probes allow for, these probes will then hybridize with 
one another to create circular DNA. The ligase will then be added to form a complete 
circular DNA template, which will be utilized for amplification and fluorescently-labeled 
visualization. The red color of the puncta come from the red dye contained within the DNA 
polymerase which will utilize the primer created by the PLA probes for rolling circle 
amplification and generate up to 1000 copies of the template. That amplification remains 
with the PLA probe, which allows for localization of protein-protein via puncta. 
Both co-transfection conditions showed puncta (Figure 7), more so than their 
individual transfection cohorts, which was to be expected based upon previous research as 
well as what was seen during this project. The puncta seen are more strongly concentrated 
in CerS2+6 compared to CerS2+5, which aligns with what was seen with CerS2 mRNA in 
Figure 2B. Overall, the presence of puncta in both co-transfection conditions shows that 
these CerS isoforms not only interact at the mRNA level, but also at the protein level. 
Another experiment that should have been taken into consideration would have been co-
immunoprecipitating CerS2 with CerS and CerS6 as Co-IP is another technique used to 
identify protein-protein interactions via protein-specific antibodies. Co-IP would not have 
been able to identify any transient protein-protein interactions in the way that Duolink can 
but it would have acted as a confirmation for the dimerization of CerS2 with CerS5 and 
CerS6 if we could have immunoprecipitated both species from the co-transfections.
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Figure 7: Co-transfections of CerS2 with CerS5 or CerS6 show puncta with Duolink. 
Blue represents DAPI nuclear staining contained within the mounting media, green 
represents COX4 mitochondrial staining, and red is puncta, which indicates protein-protein 
interactions per the Duolink protocol. Both co-transfection conditions show puncta, which 
is consistent with the isoforms forming heterodimers at the cDNA levels, shown earlier by 
the qPCR results. The puncta is stronger in CerS2+6, another aspect that has shown to be 
consistent from the mRNA. The presence of puncta indicates that these CerS isoforms are 
interacting at the protein level in these fixed cells. 
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Figure 8 represents the results at the protein level of the individual CerS6 
transfection. The western blot (Figure 8A) indicates that, not only was the Lass6 antibody 
utilized indeed specific to CerS6 and there was a bolder band in the CerS2+6 co-
transfection, but also that cells overexpressing CerS2 may also be expressing endogenous 
CerS6 at the protein level, as indicated by a dark band in the CerS2 sample lane. As was 
seen in the CerS2+6 co-transfection Duolink image, CerS2+6 has the largest and darkest 
band in the entire blot, indicating a high level of protein present in that condition. The 
presence of endogenous CerS6 within cells overexpressing CerS2 could be a result of the 
more ubiquitous distribution of CerS2 compared to that of CerS6 and the need to be able to 
balance out pro- and anti-apoptotic mechanisms within each cell. As was discussed in the 
introduction, previous research had revealed a general rule about ceramide length and 
apoptosis: LC ceramides, especially C16-ceramide, are typically pro-apoptotic whereas 
VLC ceramides are generally anti-apoptotic. CerS6 and CerS5 are the isoforms responsible 
for producing C16-ceramides and their combined distribution still does not equate that of 
CerS2, so this may be a compensatory failsafe in the event that apoptosis is required in an 
area in which CerS5 or CerS6 is not prominent. 
The expected molecular weight for these bands was around 48 kDa and the 
CerS2+6 band being a little higher than expected could be due to some type of post-
translational modification (such as glycosylation, as was suspected with CerS2) or simply 
the formation of a multimer. The western blot was run at 225V for 30 minutes, which may 
not always be an ideal voltage for a polyclonal antibody such as this Lass6. For future 
experiments based upon this project, I would certainly recommend running the western 
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closer to 100V for at least an hour, if not longer to ensure that the bands reach the bottom 
of the gel. 
The lack of puncta in Figure 8B would indicate that there is no interaction between 
CerS6 and CerS2 that may be found endogenously within cells overexpressing CerS6. 
There was also no green COX4 staining present, which may have been due to the use of 
4% paraformaldehyde as the fixative agent rather than using a dehydrating agent such as -
20°C methanol.  
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Figure 8: Cells overexpressing CerS6 do not show any endogenous sister isoforms. (A) 
The western blot indicates that the Lass6 antibody was appropriate for these experiments 
as there are bands in both the hCerS6 and hCerS2+hCerS6 lanes. However, there was also 
a band present in hCerS2, which may indicate the presence of endogenous CerS6 
contained within cells overexpressing CerS2. The largest band is clearly in the 
hCerS2+hCerS6 sample lane, which is congruent with what was seen in the mRNA. (B) 
Blue is DAPI nuclear staining, found in the mounting medium. This Duolink image does 
not show any puncta (which would have been in red) or, interestingly enough, any COX4 
mitochondrial staining (which would have been in green). The lack of puncta shows that 
there are no detectable protein interactions when Lass2 and Lass6 are applied to the CerS6 
transfection, indicating the absence of CerS2 in cells overexpressing CerS6. The lack of 
green COX4 staining may be due to the PFA fixative agent or even the dilution of the 
secondary utilized. 
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Figure 9 represents the same protein findings as Figure 8, though this time for 
CerS5. Similarly to CerS6, the Lass5 antibody used in Figure 9A shows an appropriate 
amount of specificity for CerS5 as it showed the darkest band in the hCerS5 lane. It also 
showed a band in the hCerS2 lane, which indicated that cells overexpressing hCerS2 
contains both endogenous CerS5 and CerS6. Interestingly, the band in the hCerS2+hCerS5 
lane is darker than the ones associated with the negative controls as well as the one in 
hCerS6, but is not larger than the one in the hCerS5 transfection condition. That 
discrepancy in band size does not correlate with what was seen in the mRNA, which 
showed a decent increase in gene expression level in the co-transfection compared to that 
of the individual transfection condition. This could mean that changes at the mRNA level 
do not translate to the protein level or could possibly be a result of human error when 
performing experiments. Like the other western blot, this was run at 225V for 30 minutes 
and was unable to be repeated due to time constraints. It would absolutely be of worth to 
run this blot again at a lower voltage for a longer time, as this Lass5 was also a polyclonal 
antibody. 
There are also a multitude of reasons as to why a change at the mRNA level would 
not be reflected at the protein level, such as protein degradation, rate of translation, and the 
marking of proteins to be degraded via post-translational modifications. However, a way to 
circumvent the last option would be for a protein to bind to a partner in order to decrease 
its chances of being degraded or destroyed.  
Figure 9B shows the Duolink image for the CerS5 individual transfection 
condition. The blue DAPI staining in this image seems to be distributed a bit unevenly, 
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which may have been due to the fact that the DAPI staining was contained within the 
mounting medium and was not applied to the slides otherwise. There is very little green in 
that slide despite it have received the same COX4 antibody as the others. As with the 
CerS6 slide, this may have been a result of the fixative agent or simply the incorrect 
dilution was utilized. The CerS5 slide did show puncta, however, which indicates that cells 
overexpressing CerS5 may contain some endogenous CerS2 and those proteins were 
within range for the PLA probes. The puncta seem to be located along the juxtanuclear 
region, which would be appropriate for these ER-localized enzymes. The presence of 
endogenous CerS2 within CerS5-overexpressing cells is interesting especially because 
there was no indication of any CerS2 within CerS6-overexpressing cells, the isoform 
closest in identity to CerS5. Human error could have certainly contributed to this and this 
experiment would definitely merit from some repeat experiments, but if true, this is an 
interesting indication of the differences between CerS5 and CerS6. Both catalyze the same 
length ceramides, though some previous research has shown that CerS5 and CerS6 have 
different preferences toward saturated or unsaturated fatty acyl-CoA’s (Mizutani et al., 
2005). That seems to be the main difference as of late due to difficulties in distinguishing 
between CerS5 and CerS6 activity as they utilize the same acyl-CoA. However, Duolink 
PLA is limiting in that it does not necessarily show the presence of a protein, only whether 
that protein is within 40 nm of the other of interest and if the two interact.
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Figure 9: Cells overexpressing CerS5 also express endogenous CerS2. (A) From this 
western blot run with the same Lass5 antibody used in immunofluorescence experiments, 
the darkest band is at the hCerS5 individual transfection condition. There is also a band in 
the hCerS2 transfection lane, which would mean that there is indeed endogenous CerS5 
contained within CerS2-overexpressing cells at the protein level and enough of it to 
respond to the Lass5 antibody. The bands at the two co-transfection conditions almost 
appear the same, which may be due to the presence of endogenous CerS5 within CerS2-
overexpressing cells responding to the antibody in either transfection, as previous research 
has shown that CerS2 can upregulate its enzymatic rate via dimerization. (B) The Duolink 
image of the CerS5 individual transfection shows puncta juxtanuclear to one of the cells, 
indicating that there may be endogenous CerS2 found within cells overexpressing CerS5. 
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Figure 10A showed that the Lass2 antibody used was quite specific, as the only 
bands present are in transfection conditions that contained CerS2. Again, unlike what the 
mRNA had shown, the largest band is in the hCerS2 individual transfection, though the 
band in hCerS2+hCerS6 does seem to be larger than the one in hCerS2+hCerS5, which 
was shown in the mRNA. The band size in hCerS2 may be a result of, again, the changes 
at the mRNA level not translating to those at the protein level, or it may be due to post-
translational modifications that occurred while the protein was being processed. 
Glycosylation and phosphorylation are the two main modifications that the CerS isoforms 
can undergo, and with the imaging showing that CerS2 may be localized to the Golgi, it 
would not be unreasonable to believe that the large CerS2 band may come from 
glycosylation of the protein. Regarding what was seen earlier with endogenous CerS2 
within CerS5-overexpressing cells via the Duolink, it may not show on the western as a 
result of it being a transient interaction and too quick or too weak for the western blot to 
pick up. 
The Duolink in Figure 10B shows some contrasting information to what had been 
seen previously regarding the presence of endogenous CerS5 within cells overexpressing 
CerS2 as there is no puncta present when CerS2 was subjected to Lass2 and Lass5. This 
may be a result of the initial CerS5/Lass5 western blot needing to be rerun or it could have 
resulted from the time that these cells were fixed for preparation. Both the western blot and 
Duolink are intended to illuminate as to what goes on at the protein level so this 
discrepancy is certainly one that would merit some additional testing though, again the 
Duolink PLA does not necessarily indicate presence of protein, just whether there is an 
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interaction between the two proteins of interest. Co-immunoprecipitation would be a tool 
of value to use at this point. 
The Duolink with Lass2 and Lass6 does show some robust puncta juxtanuclear to 
the cells, which does correspond to what was seen with the CerS6/Lass6 western blot. All 
blots were run under the same conditions at the same time but again, the risk of human 
error is always present in such experiments. The western and the Duolink do coincide with 
their findings, which would make a strong argument for the presence of endogenous CerS6 
within cells overexpressing CerS2, which again may come from the need to modulate pro- 
and anti-apoptotic lipids throughout the body.  
44 
Figure 10: Cells overexpressing CerS2 interact with CerS6 but may not with CerS5. 
(A) The Lass2 antibody was indeed specific to CerS2, possibly more so than Lass5 or 
Lass6 as it was a monoclonal antibody that could handle being run at a higher voltage. The 
largest band is present in the hCerS2 individual transfection rather than either of the co-
transfections, which does not coincide with what was seen at the mRNA level. The band in 
hCerS2+hCerS6 does seem to be a little larger than that of hCerS2+hCerS5, which would 
coincide with what was seen at the mRNA level, but only marginally. (B) The Duolink for 
the CerS2 individual transfection is interesting because it clashes with one previous finding 
while strengthening another. There are no puncta present in the slide that received the 
Lass2 and Lass5 antibody, which would indicate a lack of interaction between CerS5 and 
CerS2 in these CerS2-overexpressing cells. However, there is puncta present when CerS2 
receives Lass2 and Lass6, indicating that there is the presence of endogenous CerS6 within 
the cells and the two isoforms are close enough to create puncta via the PLA probes and 
potentially dimerize. 
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Discussion 
 
 The comprehension of the molecular and regulatory mechanisms of ceramide 
synthases is a crucial step to take in order to better understand an incredibly important 
molecule within our bodies. As mentioned previously, ceramides are the backbone of 
bioactive sphingolipids that are interwoven with a number of processes at the cellular level. 
Ceramide and sphingolipid metabolite dysregulation can lead to issues with cellular 
apoptosis as well as cell proliferation; some common examples include Alzheimer’s, 
Huntington’s disease, cardiovascular disease, and many human cancers, all of which have 
been noted to involve some aspect of ER stress. Ceramides have also been observed to 
regulate key intracellular effectors that will actually mediate the action of those same 
ceramides regarding apoptotic instructions (Pettus et al., 2002). 
 Due to the range in chain lengths of the fatty acids produced, ceramide synthases 
are considered a family of molecules rather than simply a single molecule. Ceramide 
synthases have also been categorized into six different isoforms, with the majority of them 
being relatively similar to one another, aside from CerS1 which has been well documented 
to be both structurally and functionally distinct from its sisters (Sridevi et al., 2010; Min et 
al., 2007). Of the six, CerS2 and CerS5 are considered the isoforms with the best 
understood regulatory mechanisms while CerS6 remains mostly a mystery. CerS5 and 
CerS6 actually share a high level of identity and similarity and CerS6 seems to be an ER-
residing protein like CerS2. However, CerS5 and CerS6 have different distributions 
throughout the body and seem to have different substrate preferences regarding unsaturated 
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or saturated fatty acyl-CoA’s (Mizutani et al., 2005), though both can and do utilize 
palmitoyl-CoA to produce C16-ceramides as they share substrate specificity levels 
(Novgorodov et al., 2010). 
 This project was focused on CerS2, CerS5, and CerS6 with a primary aim of 
determining whether co-overexpression affected localization and/or enzyme expression 
levels as measured by using immunofluorescence. Past research has shown that ceramide 
synthase activity was augmented in microsomes, with ceramidase activity present in 
mitochondrial fractions and mitochondria-associated membranes (Mullen et al., 2013). 
Novgorodoc and Gudz, in 2009, found that mitochondrial enzymes showed twice as much 
CerS activity as compared to those from the ER. CerS6 expression, interestingly, had been 
observed to have no effect on mitochondrial ceramide localization or mitophagy, with the 
researchers believing that subcellular localization of ceramides, rather than their acyl chain 
lengths, played a large role in determining their biological functions (Jiang and Ogretman, 
2013). 
 Sphingomyelinases contribute to the second known mechanism of producing 
ceramides from sphingolipids (thought of as the recycling/reverse or the acyl-CoA-
independent pathway), though its significance regarding actual ceramide production is still 
unclear as the primary mechanism is regarded as the de novo process using ceramide 
synthases. CerS2 and CerS5 have both been found to localize to the ER (Mizutani et al., 
2005; Laviad et al., 2007), though it is of worth to note that Wenger et al., in 2016, were 
unclear regarding if discrete localizations of each isoform may be due to unspecific 
antibodies, artifacts, or cellular modifications. Wenger et al. had seen that there were 
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differences in localization of CerS5 and CerS6, possibly due to cellular remodeling or 
antibody cross-reactivity. 
 Via qPCR in 2012, Laviad et al. found that, while CerS2 mRNA has the highest 
levels and the broadest tissue distribution of the isoforms, it also had the lowest in vitro 
enzymatic activity. In mammals, CerS2 activity is the most upregulated (to the point where 
Wenger et al. postulated that it may even act as a housekeeping gene in 2016) and requires 
both more time and higher protein concentration in order to match the same enzymatic 
levels as the other isoforms (Zelnik et al., 2019). That lack of enzymatic activity was the 
basis for Zelnik et al.’s 2019 study on whether CerS2 dimerizes in order to augment its 
activity levels. Mesicek et al., in 2010, had also postulated that there may be a physical 
interaction between the CerS isoforms. In 2012, Laviad et al. looked into further qualifying 
how CerS activity is regulated and found that, not only can CerS form dimers and co-
immunoprecipitate together, but CerS2 activity was enhanced upon co-overexpression with 
both CerS5 and CerS6. The researchers had also found that, in a heterodimer of CerS2 and 
CerS5, the activity of CerS2 depended upon the catalytic activity of CerS5. 
 Generally, an mRNA increase would indicate an increase in protein levels, though 
the comprehension of CerS expression at the mRNA level is still one to be furthered as it is 
considerably still uncharacterized. RT qPCR primers also do have different binding 
affinities, which may have affected the overall read of each gene’s expression level. 
Regarding the large band in the Lass2 blot (Figure 10A) and any post-translational 
modifications that the CerS may undergo, glycosylation has not been deemed for their 
enzymatic activities (Novgorodov and Gudz, 2009). CerS2, CerS5, and CerS6 are all N-
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glycosylated (Mizutani et al., 2005). CerS2 through CerS6 are also phosphorylated at the 
C-terminal, with CerS2 activity being heavily reliant upon this specific post-translational 
modification while the activities of CerS5 and CerS6 are only mildly increased (Sassa et 
al., 2016). Phosphorylation of ceramide synthases seems to be a more likely occurrence for 
these enzymes, though Sassa et al. has seen that hyperactivation of the CerS species by 
phosphorylation may worsen pathological conditions if sphingolipid species accumulate. 
Regarding this project and any future endeavors, it absolutely would have been of worth to 
test for glycosylation versus phosphorylation of these species by utilizing a phosphorylated 
version of these antibodies, though none seem to be commercially available at this time. 
Another option within that same vein would have been to subject the samples to enzymatic 
deglycosylation as it has been seen that CerS5 activity increases upon deglycosylation in 
vitro (Wegner et al., 2016). Glycosylation could have also played a part in why the CerS2 
individual transfection condition Duolink did not show any puncta when probed with 
Lass2 and Lass5 (Figure 10B). 
 In HeLa cells in 2012, Sassa et al. found that the knockdown of the CERS2 gene 
caused a downstream decrease in C24-ceramide while also creating a compensatory 
increase in C16-ceramide; said compensation may be the basis for the presence of 
endogenous CerS6 (and possibly CerS5) within cells overexpressing CerS2 at the protein 
level. Long-chain (C16) and very long-chain (C24) sphingolipids are the two most 
predominant forms found in most mammalian tissues and their functions range widely 
enough to the point where dysfunction or dysregulation could be major pathological issues. 
LC and VLC sphingolipids are produced mainly by CerS6 or CerS5 and CerS2, 
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respectively, and have been found to co-exist in order to maintain the proper balance 
between pro- and anti-apoptotic behavior in the body. 
 Between the qPCR’s, the western blots, and the Duolink images, it can be said that 
the transfections, primers, and antibodies all work at both the mRNA and protein level, 
though there was not as much visible change with the protein as was with the mRNA. To 
further confirm transfection identities for a repeat of this project, a lipidomic study could 
have been done for the samples, which was ultimately unable to be included in this project. 
Another experiment that would have been of worth doing and has been mentioned 
previously in this thesis would have been co-immunoprecipitation of CerS2 with either 
CerS5 or CerS6 in order to further validate changes seen at the protein level with co-
overexpression. SDS-PAGE and western blotting has confirmed that CerS2 
immunoprecipitates with CerS6 and CerS5 can immunoprecipitate with both CerS2 and 
CerS6 (Laviad et al., 2012; Mesciek et al, 2010).  
 Via immunofluorescence, it was shown that CerS2 does localize to the cell 
differently compared to that of CerS5 and CerS6 in that CerS2 is brightest immediately 
juxtanuclear around the ER as well was in the Golgi. CerS1, the most structurally unique 
isoform, has been able to translocate to the Golgi under certain stressors or 
chemotherapeutic drugs, though that same behavior was not seen in CerS5 when tested 
(Min et al., 2007; Sridevi et al., 2010). All three of the CerS of interest to this project have 
previously been shown to localize to the ER, which was reinforced with this project via 
immunofluorescence experiments, though CerS5 and CerS6 both appear to also localize to 
the mitochondria.
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